Efficacy of Telitacicept in Childhood‐Onset Systemic Lupus Erythematosus: A Prospective Multicenter Cohort Study With Inverse Probability of Treatment Weighting–Adjusted Comparison to a Historical Control Group Treated With Belimumab
Authors' conclusion
Telitacicept combined with SoC exhibited significant improvements in disease activity, steroid reduction, and immunologic markers, with therapeutic outcomes comparable to belimumab in cSLE management.
Study context
- Population
- Patients aged 5 to 18 years with childhood-onset SLE, seven tertiary hospitals in Chinamedian follow-up 12 [IQR 6–12] months
- Participants
- 60 vs 67
- Exposure
- Telitacicept plus standard of care (SoC) vs historical control treated with belimumab plus SoC
- Telitaciceptn = 60
- Belimumabn = 67reference
- Outcome
- Proportions attaining LLDAS and DORIS remission at 3, 6 and 12 months, with relapse rates and steroid tapering metrics
- Follow-up
- 3, 6 and 12 months
Methodological detailsmulticentre, inverse probability of treatment weighting (IPTW)-adjusted comparison to a historical control group
- Multicentre
- IPTW-adjusted comparison to a historical control group
Main finding
As reported in the abstract
6 and 12 months
- Lupus Low Disease Activity State (LLDAS) at 6 months
- 19.6%
- Definition of Remission in SLE (DORIS) at 6 months
- 7.8%
- LLDAS at 12 months
- 65.7%
- DORIS at 12 months
- 37.1%
- IPTW-adjusted: comparable efficacy telitacicept vs belimumab across all endpoints (LLDAS, DORIS, steroid reduction, immunologic normalization)
- all P > 0.05
Observational data: associations, not effects.
Further findings
Flare rates (telitacicept) · 3, 6, 12 months
- 3 months
- 1.7%
- 6 months
- 11.8%
- 12 months
- 14.3%
Prednisone ≤7.5 mg/day (telitacicept) · 12 months
- 12 months vs baseline 13.3%, P < 0.0001
- 74.3%
Original publication
Efficacy of Telitacicept in Childhood‐Onset Systemic Lupus Erythematosus: A Prospective Multicenter Cohort Study With Inverse Probability of Treatment Weighting–Adjusted Comparison to a Historical Control Group Treated With Belimumab. Arthritis Rheumatol. Published 28 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →